Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 249-257

  Schneider, Bryan J ^a   Kalemkerian, Gregory P ^b,f   Bradley, Deborah ^c   Smith, David C ^b,f   Egorin, Merrill J ^d   Daignault, Stephanie ^e   Dunn, Rodney ^e   Hussain, Maha ^b,f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f C350 Med Inn ^*  (United States)

Author keywords

Continuous reassessment method; Docetaxel; Pharmacokinetics; Phase I; Solid tumor; Vorinostat

Indexed keywords

DOCETAXEL; NSC 701852; UNCLASSIFIED DRUG; VORINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER RELAPSE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSITIONAL CELL CARCINOMA;

EID: 84856557385     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9503-6     Document Type: Article

References (56)

1. Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545-579 (Pubitemid 28411138)
2. Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343-2350 (Pubitemid 37236391)
3. Hess-Stumpp H (2005) Histone deacetylase inhibitors and cancer: From cell biology to the clinic. Eur J Cell Biol 84:109-121 (Pubitemid 40353056)
4. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428 (Pubitemid 34587077)
5. Xu W, Ngo L, Perez G et al (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitors. Proc Natl Acad Sci USA 103:15540-15545 (Pubitemid 44625628)
6. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 5:981-989 (Pubitemid 350080267)
7. Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and vorinostat inhibitors. Nature 401:188-193 (Pubitemid 29436325)
8. Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202 (Pubitemid 33741894)
9. Kelly WK, O'Connor OA, Marks PA et al (2002) Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs 11:1695-1713 (Pubitemid 35469917)
10. Cohen LA, Marks PA, Rifkind RA et al (2002) Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22:1497-1504 (Pubitemid 34839156)
11. Bali P, Pranpat M, Swaby R et al (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 11:6382-6389 (Pubitemid 41262970)
12. Mann BS, Johnson JR, He K et al (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13:2318-2322 (Pubitemid 46698579)
13. Peart MJ, Tainton KM, Ruefli AA et al (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471 (Pubitemid 36951018)
14. Butler LM, Agus DB, Scher HI et al (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
15. Seo SK, Jin HO, Lee HC et al (2008) Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 73:1005-1012
16. Krug LM, Curley T, Schwartz L et al (2006) Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 7:257-261 (Pubitemid 43280028)
17. Zhang C, Richon V, Ni X et al (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous Tcell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052
18. Palazzo A, Ackerman B, Gundersen G (2002) Cell biology: Tubulin acetylation and cell motility. Nature 421:230
19. Hubbert C, Guardiola A, Shao R et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458 (Pubitemid 34563539)
20. Zhang Y, Li N, Caron C et al (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Embo J 22:1168-1179 (Pubitemid 36313600)
21. Ringel I, Horwitz SB (1991) Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291
22. Rao S, Krauss NE, Heerding JM et al (1994) 3'-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino acids of betatubulin. J Biol Chem 269:3132-3134
23. Rao S, Orr GA, Chaudhary AG et al (1995) Characterization of the Taxol Binding Site on the Microtubule: 2-(m-AZIDOBENZOYL) TAXOL PHOTOLABELS A PEPTIDE (AMINO ACIDS 217-231) of β-TUBULIN. J Biol Chem 270:20235-20238
24. Rao S, He L, Chakravarty S et al (1999) Characterization of the Taxol Binding Site on the Microtubule: IDENTIFICATION OF Arg282 IN β-TUBULIN AS THE SITE OF PHOTOINCORPORATION OF A 7-BENZOPHENONE ANALOGUE OF TAXOL. J Biol Chem 274:37990-37994 (Pubitemid 30026868)
25. Nogales E, Wolf SG, Downing KH et al (1998) Structure of the | [alpha]||[beta]| tubulin dimer by electron crystallography. Nature 391:199-203 (Pubitemid 28092482)
26. Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem-Anti-Cancer Agents 5:65-71 (Pubitemid 40081295)
27. Blagosklonny MV, Robey R, Sackett DL et al (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937-941
28. Baker SD, Sparreboom A, Verweij J (2006) Clinical pharmacokinetics of docetaxel recent developments. Clin Pharmacokinet 45:235-252 (Pubitemid 43327491)
29. Rubin EH, Agrawal NG, Friedman EJ et al (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12:7039-7045 (Pubitemid 44974501)
30. Cockroft DW, Gauld MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
31. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
32. Goodman SN, Zahurak ML, Piantadosi S et al (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161
33. O'Quigley J, Shen LZ (1996) Continual reassessment method: A likelihood approach. Biometrics 52:673-684 (Pubitemid 26187071)
34. Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177-1182
35. Parise RA, Holleran JL, Beumer JH et al (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), an its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 840:108-115 (Pubitemid 44163473)
36. Parise RA, Ramanathan RK, Zamboni WC et al (2003) Sensitive liquid chromatography-mass spectrometry assay fro quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783:231-236 (Pubitemid 35351650)
37. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, lagrange, and spline approximation. J Pharmacokinet Biopharm 6:79-98 (Pubitemid 8314204)
38. Rocci ML Jr, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203-216 (Pubitemid 13024491)
39. Florian JA, Zamboni WC, Eiseman JL, et al. A physiologicallybased pharmacokinetic model for docetaxel distribution in SCID mice bearing SKOV-3 human ovarian cancer xenografts. J Pharmacokinet Pharmacodynam (in press).
40. D'Argenio DZ, Schumitzky A (1997) Adapt II user's guide: Pharmacokinetic/Pharmacodynamic systems analysis software. Los Angeles (CA): Biomedical Simulations Resource
41. Kloft C, Wallin J, Henningsson A et al (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: Comparison across anticancer drugs. Clin Cancer Res 12:5481-5490 (Pubitemid 44497264)
42. Bruno R, Hille D, Riva A et al (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196 (Pubitemid 28041598)
43. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692 (Pubitemid 46273572)
44. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5:37-50
45. Owonikoko TK, Ramalingam SS, Kanterewicz B et al (2010) Vorinostat increases carboplatin and paclitaxel activity in nonsmall- cell lung cancer cells. Int J Cancer 126:743-755
46. Kelly WK, O'Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, Suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931 (Pubitemid 46218695)
47. Cheung EM, Quinn DI, Tsao-Wei DD, et al (2008) Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy-California Cancer Consortium/ University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol 26 (May 20 suppl) abstr 16058
48. Bradley DA, Rathkopf D, Dunn R et al (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 115:5541-5549
49. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care inpatients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
50. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362 (Pubitemid 30415821)
51. Ramalingam SS, Parise RA, Ramananthan RK et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605-3610 (Pubitemid 46955122)
52. Ramalingam SS, Maitland ML, Frankel P et al (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56-62
53. Traynor AM, Dubey S, Eickhoff JC et al (2009) Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network Phase II Study. J Thorac Oncol 4:522-526
54. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520 (Pubitemid 39315318)
55. Cooper AL, Greenberg VL, Lancaster PS et al (2007) In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol 104:596-601 (Pubitemid 46240243)
56. Miyanaga A, Gemma A, Noro R et al (2008) Anti-tumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: Development of a molecular predictive model. Mol Cancer Ther 7:1923-1930.